AVTR
Hot AirAI neutralAvantor, Inc. · Healthcare · United States · $11.7B cap · $153.7M/day traded
$15.73 +1.0% · close 11 Nov · scored 12 Nov
Hot Air: Strong momentum and nothing else: weak business, rich price.
After its 28 Oct results, analysts raised next year's EPS estimate 1.4%.
As of 12 Nov 2026, the MoatMap Score for Avantor, Inc. (AVTR) is 74/100, ranked against 25,000+ stocks in 38 markets (Quality 45, Value 48, Momentum 77, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
Avantor supplies lab chemicals, consumables and bioprocessing materials to pharmaceutical and research customers. The shares rose sharply after second-quarter 2026 results showed one segment had stopped shrinking, and a new chief financial officer was appointed. The business still carries meaningful debt from past acquisitions and has struggled for growth, so the recovery is at an early stage and not yet proven.
ABOUT AVANTOR, INC.
Read
Avantor, Inc. is a global provider of mission-critical products and services, supporting customers in the life sciences, advanced technologies, and applied materials sectors. The company benefits from its deeply embedded position in customer workflows, offering a vast portfolio of high-quality materials, equipment, and tailored services essential for research, development, and production. This indispensable role and extensive supply chain integration provide Avantor with a significant competitive moat.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 7.5B | 7.0B | 6.8B | 6.6B | -4.5% | 6.6B | 6.7B | 6.9B | 2.3% |
| EPS | 1.02 | 0.48 | 1.05 | -0.78 | 1.5% | 0.50 | 0.82 | 0.89 | -5.5% |
| Shares | 674.3M | 676.6M | 680.8M | 682.0M | +1.1% | 677.6M | — | — | — |
| Debt | 6.3B | 5.5B | 4.1B | 3.9B | -14.4% | 3.7B | — | — | — |
| Equity | 4.9B | 5.3B | 6.0B | 5.6B | 4.7% | — | — | — | — |
| Op CF | 843.6M | 870.0M | 840.8M | 623.8M | -9.6% | 584.7M | — | — | — |
| Inv CF | -109.6M | -143.7M | 438.9M | -130.5M | — | — | — | — | — |
| Fin CF | -648.7M | -843.7M | -1.3B | -409.4M | — | — | — | — | — |
Above its 200-day average and 10% below its 52-week high.
Swung more than 52% of stocks we rank over the past year (volatility 43% a year).
How this is worked out
The MoatMap Score weighs the business, its price and its trend. The price check reads only the chart: the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AVTR are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| AVTR | Avantor, Inc.(you) | $11.7B | 74 |
| BAX | Baxter International Inc. | $13.1B | 74 |
| COO | The Cooper Companies, Inc. | $11.6B | 68 |
| SOLV | Solventum Corporation | $14.5B | 66 |
| ALGN | Align Technology, Inc. | $11.0B | 88 |
| ATR | AptarGroup, Inc. | $8.0B | 65 |
| RGEN | Repligen Corporation | $11.2B | 53 |
| TFX | Teleflex Incorporated | $5.8B | 65 |
| ICUI | ICU Medical, Inc. | $4.2B | 72 |
| WST | West Pharmaceutical Services, Inc. | $27.6B | 81 |
Peer medians: ROE -31.0% · P/E 25.7x · Gross margin 63.3%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.